Proteomics—the missing link between GWAS, EWAS, and disease endpoints
Genome-wide association studies (GWAS) and epigenome-wide association studies (EWAS) are powerful tools for identifying disease pathways, but the associations are typically weak and hard to interpret. Additionally, the complicated gene expression landscape—which is composed of interconnected cycles of transcript, protein, and metabolite levels—cannot be reliably inferred from gene sequences and chromosome modifications alone.
In this webinar, Karsten Suhre, Director of the Bioinformatics Core at Weill Cornell Medicine-Qatar, will discuss how proteomics can complement GWAS and EWAS in order to identify SNP-protein (pQTLs) and CpG-protein associations (pQTMs) and link variation in the genetic code and DNA methylation patterns to disease endpoints.
In a recent Nature Communications manuscript, Dr. Suhre and collaborators measured 1,123 circulating proteins using the SomaScan® Assay. They then made connections between protein abundance and methylation levels at >470,000 CpG sites to identify 98 highly significant pQTMs (out of >12,000 total). In this webinar, Dr. Suhre will discuss these and earlier findings from GWAS and explore how the SomaScan Assay can be used as a tool in multi-omics studies.
Karsten Suhre, PhD
Professor of Physiology and Biophysics and Director of the Bioinformatics Core, Weill Cornell Medicine-Qatar
Karsten Suhre is a Bioinformatician and Systems Biologist studying human disease at the intersection of genomics and metabolomics. Before joining Weill Cornell Medicine in 2011, Suhre served as Professor in the Department of Biology at Ludwig-Maximilians-University in Munich, Germany and as Group Leader for Metabolomics Research at the Institute for Bioinformatics and Systems Biology of Helmholtz Center Munich. Suhre also held the position of the Director of Research at the French National Centre for Scientific Research (CNRS) where he worked for 10 years excluding a two-year stint as a Project Engineer in the German Automotive Industry. Over 180 publications and numerous international presentations are a testament to Suhre’s extensive research career and interdisciplinary expertise.
Proteomics—the missing link between GWAS, EWAS, and disease endpoints
A presentation by Karsten Suhre, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.